Patents Assigned to Global Alliance for TB Drug Development
  • Patent number: 10981891
    Abstract: The present invention relates to compounds of formula (I) including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of tuberculosis.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: April 20, 2021
    Assignees: The Global Alliance for TB Drug Development, Inc., Janssen Pharmaceutica NV
    Inventors: Anna Marie Upton, Christopher Blair Cooper, Koenraad Jozef Lodewijk Marcel Andries, Jerome Emile Georges Guillemont, Walter Marcel Mathilde Van den Broeck, Brian Desmond Palmer, Zhenkun Ma
  • Patent number: 10550092
    Abstract: The present invention relates to novel oxazolidinones (Formula I): or a pharmaceutically acceptable salt having ring A characterized by N-containing monocyclic, bicyclic or spirocyclic substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: February 4, 2020
    Assignee: The Global Alliance for TB Drug Development, Inc.
    Inventors: Christopher B. Cooper, Haihong Huang, Dongfeng Zhang, Nader Fotouhi, Takushi Kaneko
  • Patent number: 10508097
    Abstract: The present invention relates to compounds of formula (I) including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of tuberculosis.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: December 17, 2019
    Assignees: The Global Alliance for TB Drug Development, Inc., Janssen Pharmaceutica NV
    Inventors: Anna Marie Upton, Christopher Blair Cooper, Koenraad Jozef Lodewijk Marcel Andries, Jerome Emile Georges Guillemont, Walter Marcel Mathilde Van den Broeck, Brian Desmond Palmer, Zhenkun Ma
  • Patent number: 9198913
    Abstract: The present invention relates to novel nitroimidazooxazines, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: December 1, 2015
    Assignee: Global Alliance for TB Drug Development
    Inventors: William Alexander Denny, Andrew Mark Thompson, Adrian Blaser, Zhenkun Ma, Brian Desmond Palmer, Hamish Scott Sutherland, Iveta Kmentova
  • Patent number: 9163020
    Abstract: The invention provides compounds of formula (I) and methods of treating a Mycobacterium infection or tuberculosis, or inhibiting DprE1 with the same.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: October 20, 2015
    Assignees: Global Alliance for TB Drug Development, Foundation for Neglected Disease Research
    Inventors: Pravin S. Shirude, Maruti N. Naik, Vikas Narayan Shinde, Shahul Hameed Peer Mohamed, Monalisa Chatterji, Radha K. Shindil
  • Publication number: 20140243327
    Abstract: The present invention relates to riminophenazines having heteroaromatic substitutions, including those with 2-heteroaryl-amino substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments. A general representation of the 2-(heteroaryl)amino-riminophenazines is shown below.
    Type: Application
    Filed: May 1, 2014
    Publication date: August 28, 2014
    Applicant: Global Alliance for TB Drug Development
    Inventors: Kai Liu, Christopher B. Cooper, Haihong Huang, Chun Li, Binna Liu, Yang Liu, Zhenkun Ma, Jingbin Wang, Dali Yin, Dongfeng Zhang, Gang Zhang, Hao Zhang
  • Patent number: 8716292
    Abstract: The present invention relates to riminophenazines having heteroaromatic substitutions, including those with 2-heteroaryl-amino substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments. A general representation of the 2-(heteroaryl)amino-riminophenazines is shown below.
    Type: Grant
    Filed: June 28, 2011
    Date of Patent: May 6, 2014
    Assignee: Global Alliance for TB Drug Development
    Inventors: Kai Liu, Christopher B. Cooper, Haihong Huang, Chun Li, Binna Liu, Yang Liu, Zhenkun Ma, Jingbin Wang, Dali Yin, Dongfeng Zhang, Gang Zhang, Hao Zhang
  • Patent number: 8293734
    Abstract: The current invention pertains to nitroimidazooxazine and nitroimidazooxazole analogues, their methods of preparation, and uses of the compounds as treatment for Mycobacterium tuberculosis, for use as anti-tubercular drugs, for use as anti-protozoal agents with unexpectedly high potency against Trypanosoma cruzi or Leishmania donovani, and for the treatment of other microbial infections.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: October 23, 2012
    Assignee: Global Alliance for TB Drug Development
    Inventors: Andrew Mark Thompson, William Alexander Denny, Adrian Blaser, Zhenkun Ma
  • Publication number: 20120071472
    Abstract: The present invention relates to riminophenazines having heteroaromatic substitutions, including those with 2-heteroaryl-amino substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.
    Type: Application
    Filed: June 28, 2011
    Publication date: March 22, 2012
    Applicants: Institute of Materia Medica, Global Alliance for TB Drug Development
    Inventors: Kai Liu, Christopher B. Cooper, Haihong Huang, Chun Li, Binna Liu, Yang Liu, Zhenkun Ma, Jingbin Wang, Dali Yin, Dongfeng Zhang, Gang Zhang, Hao Zhang
  • Publication number: 20120028973
    Abstract: The present invention relates to novel nitroimidazooxazines, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.
    Type: Application
    Filed: July 30, 2010
    Publication date: February 2, 2012
    Applicant: Global Alliance for TB Drug Development
    Inventors: William Alexander Denny, Andrew Mark Thompson, Adrian Blaser, Brian Desmond Palmer, Zhenkun Ma, Hamish Scott Sutherland, Iveta Kmentova
  • Publication number: 20110028466
    Abstract: The current invention pertains to nitroimidazooxazine and nitroimidazooxazole analogues, their methods of preparation, and uses of the compounds as treatment for Mycobacterium tuberculosis, for use as anti-tubercular drugs, for use as anti-protozoal agents with unexpectedly high potency against Trypanosoma cruzi or Leishmania donovani, and for the treatment of other microbial infections.
    Type: Application
    Filed: July 30, 2010
    Publication date: February 3, 2011
    Applicant: Global Alliance for TB Drug Development
    Inventors: Andrew Mark Thompson, William Alexander Denny, Adrian Blaser, Zhenkun Ma
  • Patent number: 7666864
    Abstract: The current invention provides a series of bicyclic nitroimidazole-substituted phenyl oxazolidinones in which a bicyclic nitroimidazole pharmacophore is covalently bonded to a phenyl oxazolidinone, their pharmaceutical compositions, and the method of use of the compositions for prevention and treatment of bacterial infections. The bicyclic nitroimidazole-substituted phenyl oxazolidinones possess surprising antibacterial activity against wild-type and resistant strains of pathogens, and are therefore useful for the prevention, control and treatment of a number of human and veterinary bacterial infections caused by these pathogens, such as Mycobacterium tuberculosis.
    Type: Grant
    Filed: March 25, 2009
    Date of Patent: February 23, 2010
    Assignee: Global Alliance for TB Drug Development
    Inventors: Charles Z. Ding, Genliang Lu, Keith Combrink, Dianjun D. Chen, Minsoo Song, Jiancheng Wang, Zhenkun Ma, Brian Desmond Palmer, Adrian Blaser, Andrew M. Thompson, Iveta Kmentova, Hamish Scott Sutherland, William Alexander Denny
  • Publication number: 20090281088
    Abstract: The current invention provides a series of bicyclic nitroimidazole-substituted phenyl oxazolidinones in which a bicyclic nitroimidazole pharmacophore is covalently bonded to a phenyl oxazolidinone, their pharmaceutical compositions, and the method of use of the compositions for prevention and treatment of bacterial infections. The bicyclic nitroimidazole-substituted phenyl oxazolidinones possess surprising antibacterial activity against wild-type and resistant strains of pathogens, and are therefore useful for the prevention, control and treatment of a number of human and veterinary bacterial infections caused by these pathogens, such as Mycobacterium tuberculosis.
    Type: Application
    Filed: March 25, 2009
    Publication date: November 12, 2009
    Applicant: Global Alliance for TB Drug Development
    Inventors: Charles Z. Ding, Genliang Lu, Keith Combrink, Dianjun D. Chen, Minsoo Song, Jiancheng Wang, Zhenkun Ma, Brian Desmond Palmer, Adrian Blaser, Andrew M. Thompson, Iveta Kmentova, Hamish Scott Sutherland, William Alexander Denny